{"id":9430,"date":"2026-02-05T20:20:00","date_gmt":"2026-02-05T12:20:00","guid":{"rendered":"https:\/\/fotonmedix.com\/?p=9430"},"modified":"2026-02-04T17:14:58","modified_gmt":"2026-02-04T09:14:58","slug":"the-scientific-foundation-of-canine-photobiomodulation-beyond-the-visible-spectrum","status":"publish","type":"post","link":"https:\/\/fotonmedix.com\/fr\/the-scientific-foundation-of-canine-photobiomodulation-beyond-the-visible-spectrum.html\/","title":{"rendered":"Les fondements scientifiques de la photobiomodulation canine : Au-del\u00e0 du spectre visible"},"content":{"rendered":"

Dans le monde de la m\u00e9decine sportive v\u00e9t\u00e9rinaire et des soins de r\u00e9\u00e9ducation, la question de l'efficacit\u00e9 est souvent accueillie avec un enthousiasme anecdotique plut\u00f4t qu'avec un examen clinique rigoureux. En tant que praticien ayant deux d\u00e9cennies d'exp\u00e9rience dans l'application du laser m\u00e9dical, j'ai observ\u00e9 le passage du scepticisme \u00e0 l'adoption universelle. Cependant, pour de nombreux propri\u00e9taires d'animaux et m\u00eame pour certains m\u00e9decins g\u00e9n\u00e9ralistes, la question fondamentale reste pos\u00e9e : La th\u00e9rapie au laser est-elle efficace pour les chiens ?<\/strong>? Pour r\u00e9pondre \u00e0 cette question, nous devons d\u00e9passer la terminologie marketing et nous plonger dans la bio\u00e9nerg\u00e9tique cellulaire de la lumi\u00e8re.<\/p>\n\n\n

\n
\"\"<\/figure>\n<\/div>\n\n\n

Historiquement, le terme th\u00e9rapie au laser froid chez les chiens<\/a><\/strong> was used to distinguish low-level laser therapy (LLLT) from surgical lasers that cut or cauterize tissue. Today, we recognize that “cold” is a misnomer. Modern veterinary medicine utilizes high-intensity systems\u2014specifically Class IV lasers\u2014that provide a therapeutic warmth, which serves as a secondary vasodilatory benefit. The core of the treatment, however, is not thermal; it is photochemical.<\/p>\n\n\n\n

Bio\u00e9nerg\u00e9tique cellulaire : Le m\u00e9canisme d'action<\/h3>\n\n\n\n

La r\u00e9ponse biologique \u00e0 la lumi\u00e8re laser est appel\u00e9e v\u00e9t\u00e9rinaire photobiomodulation<\/a> (PBM)<\/strong>. This is not a vague “healing energy” but a specific pharmaceutical-grade interaction between photons and cellular chromophores. The primary target is Cytochrome C Oxidase (CCO), a terminal enzyme in the mitochondrial respiratory chain.<\/p>\n\n\n\n

When a dog is suffering from chronic inflammation or acute trauma, its cells are in a state of metabolic “starvation.” Nitric oxide (NO) binds to CCO, effectively clogging the cellular engine and halting the production of Adenosine Triphosphate (ATP). When we apply laser therapy at specific wavelengths\u2014typically in the 810nm to 980nm range\u2014the photons are absorbed by CCO, triggering the dissociation of nitric oxide.<\/p>\n\n\n\n

This dissociation allows oxygen to bind in its place, restoring the oxidative phosphorylation process. The resulting surge in ATP provides the cell with the “currency” required for repair, while the released nitric oxide acts as a potent local vasodilator, improving the microcirculation of the vasa nervorum and the surrounding musculoskeletal structures. This is why th\u00e9rapie laser pour les chiens<\/a> Est-ce que \u00e7a marche ?<\/strong>\u2014it addresses the pathology at the mitochondrial level before systemic symptoms are even managed.<\/p>\n\n\n\n

Physique de la fen\u00eatre optique canine<\/h3>\n\n\n\n

Treating a canine patient involves unique optical challenges that do not exist in human medicine. The most significant variable is the “fur barrier.” Canine hair is a highly effective filter of light, particularly in dark-coated breeds where melanin concentration is high.<\/p>\n\n\n\n

To achieve a therapeutic dose at the joint level\u2014often 3 to 7 centimeters deep in a large breed\u2014the clinician must account for the “Optical Window.” This is the spectrum of light (roughly 600nm to 1100nm) where tissue penetration is maximized because absorption by water, melanin, and hemoglobin is at its relative minimum.<\/p>\n\n\n\n

    \n
  1. 650nm (lumi\u00e8re rouge) :<\/strong> Absorb\u00e9 principalement par la peau et le derme superficiel. Excellent pour les granulomes de l\u00e9chage ou la cicatrisation des plaies superficielles, mais largement inefficace pour les affections orthop\u00e9diques.<\/li>\n\n\n\n
  2. 810nm (le d\u00e9clencheur ATP) :<\/strong> Correspond au pic d'absorption de la cytochrome C oxydase. Il s'agit de la longueur d'onde principale pour la r\u00e9g\u00e9n\u00e9ration des tissus profonds.<\/li>\n\n\n\n
  3. 915nm (longueur d'onde d'oxyg\u00e9nation) :<\/strong> Facilite la lib\u00e9ration de l'oxyg\u00e8ne de l'h\u00e9moglobine dans les tissus environnants.<\/li>\n\n\n\n
  4. 980nm (catalyseur de la douleur et de la circulation) :<\/strong> Cible l'eau du liquide interstitiel, induisant un effet thermique qui favorise la modulation de la douleur et le drainage lymphatique.<\/li>\n<\/ol>\n\n\n\n

    Sans le pouvoir d'un appareil de th\u00e9rapie laser pour chiens<\/a><\/strong> qui peuvent d\u00e9livrer plusieurs watts de puissance (par opposition aux milliwatts), les photons sont diffus\u00e9s et absorb\u00e9s par la fourrure avant m\u00eame d'atteindre le tissu cible. C'est la principale raison pour laquelle les anciens appareils de faible puissance donnaient souvent des r\u00e9sultats incoh\u00e9rents.<\/p>\n\n\n\n

    La r\u00e9ponse biphasique \u00e0 la dose : La loi d'Arndt-Schulz<\/h3>\n\n\n\n

    In clinical PBM, more is not always better. The Arndt-Schulz Law states that there is an “optimal window” of stimulation. If the dose is too low (sub-therapeutic), no biological effect occurs. If the dose is too high, it can actually inhibit healing or cause cellular damage.<\/p>\n\n\n\n

    Pour le clinicien chevronn\u00e9, l'art du traitement r\u00e9side dans le calcul des Power Density (W\/cm\u00b2)<\/strong> et le Energy Density (J\/cm\u00b2)<\/strong>. Nous devons traiter les photons comme un m\u00e9dicament ayant une concentration sp\u00e9cifique. Ceci est particuli\u00e8rement important lorsque l'on parle de Effets secondaires de la th\u00e9rapie laser pour les chiens<\/a><\/strong>. Les effets secondaires sont rares, mais ils r\u00e9sultent presque toujours d'un surtraitement (doses inhibitrices) ou d'une mauvaise technique (inconfort thermique chez les animaux \u00e0 fourrure fonc\u00e9e).<\/p>\n\n\n\n

    \u00c9volution clinique : Classe IIIb vs. classe IV<\/h3>\n\n\n\n

    The debate over Class IIIb versus Class IV lasers has largely been settled by clinical outcomes in large-breed canine orthopedics. A Class IIIb laser is limited to 500mW (0.5W). To deliver a therapeutic dose of 3,000 Joules to a hip joint with such a device would take over an hour of stationary application\u2014a logistical impossibility in a veterinary setting.<\/p>\n\n\n\n

    A Laser de classe IV<\/a>, often delivering 15 to 25 Watts, allows for a “sweeping” technique. This technique prevents the formation of thermal “hot spots” while delivering the required energy in a matter of minutes. Furthermore, the higher power output ensures that even after the fur and skin scatter 80% of the light, the remaining 20% is still sufficient to reach the therapeutic threshold at the joint capsule. This efficiency is the cornerstone of modern Laser de classe IV pour l'arthrose canine<\/strong> (arthrose).<\/p>\n\n\n\n

    \u00c9tude de cas clinique : Prise en charge de l'arthrose multi-articulaire chez un chien d'assistance<\/h3>\n\n\n\n

    Pour illustrer l'application pratique de la th\u00e9rapie laser de haute intensit\u00e9, examinons un cas clinique d\u00e9taill\u00e9 trait\u00e9 dans un h\u00f4pital v\u00e9t\u00e9rinaire multidisciplinaire.<\/p>\n\n\n\n

    Ant\u00e9c\u00e9dents du patient :<\/strong><\/p>\n\n\n\n

    “Buster,” an 11-year-old male neutered Labrador Retriever, retired search and rescue dog. Buster presented with a 2-year history of progressive mobility decline. Despite being on a multimodal pharmaceutical plan (NSAIDs, Gabapentin, and Adequan), his owners reported significant “morning stiffness” and an inability to climb the three stairs to his sleeping area.<\/p>\n\n\n\n

    Diagnostic pr\u00e9liminaire :<\/strong><\/p>\n\n\n\n

    L'examen physique et les radiographies ont confirm\u00e9 une maladie bilat\u00e9rale s\u00e9v\u00e8re du compartiment m\u00e9dian (arthrose du coude) et une dysplasie bilat\u00e9rale concomitante de la hanche avec une atrophie musculaire significative des membres pelviens. L'\u00e9chelle visuelle analogique (EVA) de la douleur \u00e9tait de 8\/10 pendant l'activit\u00e9.<\/p>\n\n\n\n

    Strat\u00e9gie de traitement :<\/strong><\/p>\n\n\n\n

    The goal was to utilize high-intensity PBM to reduce synovial inflammation and stimulate mitochondrial repair in the atrophied muscles. A Class IV system was selected to overcome Buster’s thick, yellow double coat.<\/p>\n\n\n\n

    Param\u00e8tres cliniques et param\u00e8tres du protocole :<\/strong><\/p>\n\n\n\n

    Param\u00e8tres<\/strong><\/td>Protocole coude (par articulation)<\/strong><\/td>Protocole hanche (par articulation)<\/strong><\/td>Raison d'\u00eatre<\/strong><\/td><\/tr><\/thead>
    Longueur d'onde<\/strong><\/td>810nm + 980nm<\/td>810nm + 980nm + 1064nm<\/td>Triple longueur d'onde pour la profondeur et l'ATP<\/td><\/tr>
    Puissance de sortie<\/strong><\/td>10 Watts (puls\u00e9)<\/td>15 Watts (onde continue)<\/td>Une puissance plus \u00e9lev\u00e9e pour une articulation de la hanche plus profonde<\/td><\/tr>
    Fr\u00e9quence<\/strong><\/td>1000 Hz<\/td>500 Hz<\/td>Fr\u00e9quence plus basse pour une p\u00e9n\u00e9tration plus profonde<\/td><\/tr>
    \u00c9nergie totale<\/strong><\/td>3000 joules<\/td>6000 joules<\/td>Dose compl\u00e8te pour l'arthrose chronique<\/td><\/tr>
    Densit\u00e9 de puissance<\/strong><\/td>5,0 W\/cm\u00b2<\/td>7.5 W\/cm\u00b2<\/td>Optimis\u00e9 pour la densit\u00e9 du pelage du Labrador<\/td><\/tr>
    Dur\u00e9e du traitement<\/strong><\/td>5 minutes<\/td>8 minutes<\/td>Mouvement de balayage pour \u00e9viter les points chauds<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

    Le processus de traitement :<\/strong><\/p>\n\n\n\n

    Buster received an “induction” phase of three sessions per week for two weeks, followed by a “transition” phase of twice per week for two weeks. During the sessions, Buster was observed to relax, eventually lying down and resting his head\u2014a common response to the release of \u03b2-endorphins triggered by the 980nm wavelength.<\/p>\n\n\n\n

    R\u00e9cup\u00e9ration et r\u00e9sultats apr\u00e8s le traitement :<\/strong><\/p>\n\n\n\n